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Abstract
Decades of research have established that the most effective treatment for sickle cell disease (SCD) is increased fetal
hemoglobin (HbF). Identification of a drug specific for inducing c-globin expression in pediatric and adult patients, with
minimal off-target effects, continues to be an elusive goal. One hurdle has been an assay amenable to a high-throughput
screen (HTS) of chemicals that displays a robust c-globin off-on switch to identify potential lead compounds. Assay systems
developed in our labs to understand the mechanisms underlying the c- to b-globin gene expression switch during
development has allowed us to generate a cell-based assay that was adapted for a HTS of 121,035 compounds. Using
chemical inducer of dimerization (CID)-dependent bone marrow cells (BMCs) derived from human c-globin promoter-firefly
luciferase b-globin promoter-Renilla luciferase b-globin yeast artificial chromosome (c-luc b-luc b-YAC) transgenic mice, we
were able to identify 232 lead chemical compounds that induced c-globin 2-fold or higher, with minimal or no b-globin
induction, minimal cytotoxicity and that did not directly influence the luciferase enzyme. Secondary assays in CID-
dependent wild-type b-YAC BMCs and human primary erythroid progenitor cells confirmed the induction profiles of seven
of the 232 hits that were cherry-picked for further analysis.
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Introduction
Sickle cell disease (SCD) is the most common monogenetic
disease diagnosed in the United States, affecting approximately 1
of 400 African-American infants [1]. The high morbidity rate of
SCD patients is related to vascular complications that include
multiple chronic organ damage affecting the brain, heart, lungs,
kidneys, liver, eyes, skin, and skeleton. Vaso-occlusive crises result
in acute and chronic severe pain, as well as acute chest syndrome,
splenic sequestration, hemolytic anemia, stroke, acute and chronic
multi-system organ damage, and shortened life expectancy [2],
[3]. Understanding the molecular mechanisms underlying the
human c- to b-globin gene switch has long been recognized as
important in the treatment of SCD, since a wealth of evidence has
demonstrated that increased fetal hemoglobin (HbF) significantly
ameliorates the clinical complications associated with this disease
Individuals with defective adult b-globin genes, as is the case for
SCD or b-thalassemia, are more-or-less phenotypically normal if
they carry compensatory mutations that result in hereditary
persistence of fetal hemoglobin (HPFH). Thus, a logical clinical
goal for treatment of the b-hemoglobinopathies is to up-regulate
c-globin synthesis pharmacologically.
An increase in HbF parameters (% HbF and % F cells) prevents
sickling in vivo. Hydroxyurea (HU), a ribonucleotide reductase
inhibitor that arrests DNA synthesis, was shown to increase HbF
production and improve the clinical symptoms of SCD [4], [5].
HU is currently the only FDA-approved drug to treat SCD, but
the side effects and safety issues associated with long-term use are
unknown [6]. Fetal hemoglobin synthesis can be stimulated by
several other pharmacologic compounds including 5-azacytidine,
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AraC, butyrate and other short chain fatty acids [7], [8], [9], [10],
[11], [12], [13], [14]. However, therapies specific for SCD, that do
not affect cell physiology globally, remain elusive.
High-throughput (HTS) technology has been used successfully
in the past 20 years in the pharmaceutical industry for lead drug
discovery [15], [16]. Development of the technology has been
propelled by advancements in combinatorial chemistry, human
genome sequencing, and automation of drug screens. It is an
enabling technology and the number of researchers that have
applied this powerful tool in biomedical research has increased.
Successful examples include discoveries of novel inhibitors of
protein arginine methyltransferase [17], metalloform-selective
methionine aminopeptidase [18], and cystic fibrosis transmem-
brane conductance regulator [19].
Based on our previous data using wild-type CID-dependent
b-YAC BMCs, we generated dual-luciferase b-YAC (dual-luc
b-YAC) BMCs containing c-globin promoter-firefly luciferase (c-
luc) and b-globin promoter-Renilla luciferase (b-luc) fusions from
c-luc b-luc b-YAC transgenic mice. The c-luc gene fusion was not
active unless a c-globin inducing compound was applied, a true
‘‘off-on’’ switch similar to our wild-type CID-dependent b-YAC
BMCs, whereas the b-luc gene fusion was active. These cells were
adapted to a HTS platform to allow rapid identification of
chemical scaffolds that produced firefly luciferase-positive cells
(c-globin), but did not further induce Renilla luciferase (b-globin).
Out of 121,035 compounds tested, 233 lead compounds that
induce c-globin gene expression were identified in this cell-based
HTS system.
Materials and Methods
Detailed Materials and Methods may be found in the
accompanying Supplemental Materials and Methods file (File S1).
Generation of the dual-luc b-YAC construct, production
of transgenic mice and derivation of CID-dependent
BMCs
A firefly luciferase gene cassette was incorporated into the Ac-
globin gene (Figure 1A) of a 155 Kb b-YAC [20] and the resultant
c-luc b-YAC was modified by introduction of a Renilla luciferase
gene cassette into the b-globin gene using homologous recombi-
nation in yeast [21] for both steps, essentially as described [22].
The resultant b-YAC was purified and microinjected into fertilized
oocytes to produce transgenic mice [23]. CID-dependent BMCs
were established from these animals and maintained as previously
[24].
Ethics Statement
The mouse work was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee of the University of Kansas Medical Center (ACUP
Number: 2012–2060). All efforts were made to minimize suffering.
High-throughput screening assay
For HTS experiments, the dual luc b-YAC BMCs were seeded
into 384-well plates (Greiner Bio-One, Monroe, NC) at a density
of 10,000 cells/30 ml/well by Wellmate bulk dispenser (Thermo-
Scientific Inc., Waltham, MA) in complete media containing the
CID, CL-COB-II-293 (synthesized by the University of Kansas
COBRE CCET Core C Synthesis Lab, commonly called
AP20187). The CID-dependent dual luc b-YAC BMCs were
responsive to known c-globin inducers including valproic acid,
sodium butyrate, valeric acid and hydroxyurea (data not shown).
Sodium butyrate (2 mM) was selected as the positive control for
screening, as a consistent 5–6 fold increase in firefly luciferase
activity was obtained in four independent experiments with four
different passage numbers. Since both the cell viability and
luciferase induction was unaffected at DMSO concentrations
below 0.5%, the compound libraries were screened at 10 mM
concentration in 0.35% DMSO. Compounds were transferred
acoustically using a Labcyte Echo 550 dispenser (Labcyte Inc.,
Sunnyvale, CA). Based on previous optimizations, 10,000 cells/
well in IMDM containing CL-COB-II-293 (100 nM) were added
to the wells of 384-well assay plates. The negative (n = 16, DMSO)
and positive (n = 16, sodium butyrate, 2 mM) controls were added
to the first two columns of each plate to assure uniformity across
plates and screening batches. The cells were exposed to
compounds for 24 hours at 37uC, 5% CO2 in a 95% humidified
incubator. After 24 hours incubation, Steady Glo luciferase
detection reagent (Promega, Madison, WI) was used for cell lysis
and generation of a luminescent signal, proportional to c-globin
promoter driven firefly luciferase reporter expression. The
luminescence intensities were read 30 minutes later on a Tecan
Safire2 microplate reader (Tecan, Männedorf, Switzerland). The
luminescence values were used for calculating fold-induction of
luciferase over DMSO treated controls. The controls were used to
calculate a Z9 factor value for each plate, a measure of screening
assay quality.
Compound libraries. For this study, the optimized cell-
based assay utilized the following six compound collections: 1)
MicroSource Spectrum (2,000 compounds containing FDA
approved drugs, bioactive, natural products, MicroSource Dis-
covery Systems, Gaylordsville, CT, www.msdiscovery.com), 2)
Prestwick Chemical Library (1,120 compounds, Prestwick Chem-
ical, ILLKIRCH France), 3) The University of Kansas Center of
Excellence in Chemical Methodologies & Library Development
(KU-CMLD, 1,920 compounds with novel diverse scaffolds), 4)
ChemBridge Library (43,736 drug-like diverse chemical structures,
ChemBridge Corporation, San Diego, CA, www.chembridge.
com), 5) ChemDiv Library (56,232 compounds, diversity set from
ChemDiv Inc., San Diego, CA), and 6) Orthogonally Compressed
Library [(OCL), collection of 16,000 compounds from The
Lankenau Institute for Medical Research (LIMR), Chemical
Genomics Center (LCGC) Inc., Wynnwood, PA).
Data analysis. The active compounds from the primary
screen were cherry-picked from mother plates and retested for
firefly luciferase induction in an eight concentration dose-response
assay (two fold dilution starting at 30 mM). The fold-induction
values from dose-response curves were used for preliminary
scaffold analysis and clustering using the Tripos Selector program
and analyzed using the Jarvis Patrick routine, using default
parameters [The Tripos Associates (Cetara), St. Louis, MO]. From
each preliminary cluster, the largest conserved substructure
present in at least half of the cluster members was identified.
Secondary screening. Some of the primary screen active
compounds were repurchased and tested for activity in cell-based
assays using the primary screening reporter cells in a ten
concentration dose-response. Both firefly luciferase induction (c-
globin promoter activation using the One-Glo luciferase detection
system; Promega, Madison, WI), and Renilla luciferase induction
(b-globin induction the using Renilla-Glo Luciferase detection
system; Promega, Madison, WI), were measured for specificity of
compound activity. The cytotoxicity of the compounds was
measured after 24 hours in the same cells using Cell-Titer Glo
reagent (Promega, Madison, WI). The compounds were also tested
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Figure 1. Schematic diagrams of the b-YAC construct and HTS work flow. Panel A) c-luc b-luc b-YAC construct used to generate transgenic
mice and derivative CID-dependent murine BMCs. This b-YAC was assembled as described in Materials and Methods and was derived from the Ppo-
155 b-YAC [22]. The b-YAC is indicated as a line with the b-like globin genes or b-like globin promoter-luciferase fusions shown as boxes with the
names of the genes above them. More detailed information regarding the components of the two luc fusions are indicated above and below the b-
YAC illustration. Boxes at the left and right ends are modified pYAC4 vector [42] sequences. The LCR 59HSs, 39HS1 and YAC/yeast gene components
are indicated above the line. LYS2, yeast lysine synthesis gene; ARS1, autonomous replicating sequence (yeast origin of replication); CEN1, yeast
centromere; TRP1, yeast tryptophan synthesis gene; PGKneo, mammalian G418-resistance cassette. Engineered restriction enzyme sites utilized YAC
structural determinations are shown below the line. Panel B) High-throughput screening work flow and secondary assays. The process flow
of the high-throughput screen for identification of active compounds up-regulating fetal c-globin gene expression is shown. The assay utilized
immortalized multi-potential cells derived from the bone marrow of transgenic mice stably expressing a dual luciferase construct with firefly
luciferase under control of the fetal Ac-globin promoter and Renilla luciferase under the control of the adult b-globin promoter. The screening
parameters were optimized in 384-well format and the cells were characterized for their ability to respond to at least 10 known inducers of fetal
globin including hydroxyurea, sodium butyrate, valproic acid, and valeric acid. The assay was used to screen 120,035 compounds from the KU
compound collection; 232 of which were found to up regulate firefly luciferase. The actives were clustered into 12 structural groups and fresh
compounds were repurchased from various vendors. Three cell-based secondary assays were performed using the freshly available compounds: 1)
up-regulation of firefly luciferase, 2) activity of Renilla luciferase, and 3) general cytotoxicity. The active compounds were also tested for inhibition of
purified luciferase in an optimized biochemical assay. Profiling of the compounds revealed that of the 232 compounds tested, at least 124
compounds selectively up-regulated firefly luciferase but did not up-regulate Renilla luciferase. The 124 compounds which selectively up-regulated
firefly luciferase activity also did not inhibit purified luciferase enzyme activity and were largely non-toxic to bone marrow progenitor cells.
doi:10.1371/journal.pone.0107006.g001
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in a biochemical screen for any inhibition to purified firefly
luciferase enzyme (15 nM).
Verification assays for c-globin transcription and HbF
synthesis in murine CID-dependent wild-type b-YAC
BMCs or human CD34+ primary progenitor cells
Human erythroid progenitors were generated in vitro from
adult CD34+ stem cells (STEMCELL Technologies, Inc.,
Vancouver, Canada) using a 2-stage culture system that achieves
terminal erythroid differentiation [25]. Standard, but variant,
methods for quantitative reverse transcription-PCR (qRT-PCR)
and flow-activated cell sorting (FACS) were employed for the two
cell types as detailed in File S1. ELISA was used to measure HbF
in CID-dependent wild-type b-YAC BMCs as described in the
supplement.
Results
Cell-based assay system characteristics
We developed CID-dependent Ac-luc b-luc bb-YAC BMCs
from our transgenic mice as a powerful tool for screening
activators of c-globin [26]. This cell-based assay has a strong c-
globin gene expression off-on switch, a characteristic which is
lacking in existing erythroid cell lines. A chimeric growth switch
consisting of the thrombopoietin receptor (mpl) signaling domain
fused to a FKBP12 ligand-binding domain is activated on addition
of a CID. The CID, CL-COB-II-293 (AP20187), enforces
dimerization by binding two FKBP12 ligand-binding domains
on two neighboring molecules with 1:2 stoichiometry. Dimeriza-
tion causes signaling from the mpl receptor sequences. The
resultant multi-potential transgenic BMCs express exclusively
human b-globin from the wild-type b-YAC transgene [26]. c-
globin synthesis is not detected in wild-type b-YAC BMCs, but
expression can be reactivated in the presence of 5-azacytidine (5-
Aza), butyric acid and other fatty acids, hydroxyurea, or hemin.
The 150 Kb dual luc b-YAC was synthesized as described in
Materials and Methods; a schematic diagram is shown in
Figure 1A. Mouse L cells, a non-erythroid control, lipofected
with the dual luc b-YAC, constitutively expressed c-luc and b-luc,
similar to wild-type b-YAC L cell lines and induction with hemin/
HMBA was not observed (data not shown) [27], [28]. MEL585
cells or GM979 cells similarly transfected trended towards
establishing proper luciferase expression patterns appropriate to
each cell line with extended time in culture, but displayed mixed
responsiveness to terminal differentiation agents or inducers,
similar to cell lines produced with the wild-type b-YAC (data not
shown). However, both firefly and Renilla luciferase activities
steadily declined in cell pools or clones, whether induced or not,
after 28 weeks of culture.
Transgenic mice were also produced with this dual luc b-YAC.
The hematopoietic tissues of staged conceptuses were assayed for
c-firefly luciferase and b-Renilla luciferase. Generally, the two
gene fusions showed correct developmental regulation, with c-luc
predominating during primitive erythropoiesis in the yolk sac and
b-luc during the later stages of definitive erythropoiesis in the fetal
liver and in the adult bone marrow (data not shown). CID-
dependent dual luc b-YAC BMCs displayed a b-like globin gene
expression pattern that was identical to previously established
CID-dependent wild-type b-YAC BMCs, however c-firefly-luc or
b-Renilla-luc transcription/enzyme activity were the parameters
measured, rather than native c- or b-globin transcript/protein
levels. In the absence of any HbF activating compounds, these cells
were c-luc2 b-luc+ (data not shown). Using this cell-based assay, a
HTS and secondary verification assays were performed as outlined
in Figure 1B.
Primary HTS
Parameters for the HTS are described in Methods and
outcomes are summarized in Tables 1 and 2. The screening assay
was found to be robust with an acceptable dynamic range between
the positive (sodium butyrate induction) and negative DMSO
Table 1. Primary screen.
Compound Source No. of Compounds
Validation Library (Microsource, Prestwick and CMLD) 5,067
ChemBridge Library 43,736
ChemDiv Library 56,232
Orthogonally compressed library (LCGC) 16,000
Total No. of compounds 121,035
Actives: 232.
Overall hit rate: 0.19%.
doi:10.1371/journal.pone.0107006.t001
Table 2. Reordered compounds.
Compound Source No. of Compounds Amount (mgs)
ChemBridge Library 171 2
ChemDiv Library 21 2
Orthogonally compressed library (LCGC) 40 2–5
Total No. of compounds 232
100% DMSO: 50 or 100 mM.
doi:10.1371/journal.pone.0107006.t002
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vehicle baseline controls across all the plates screened. The good
separation of controls, as well as low variability around the means
of the controls, resulted in an average Z9 factor value of 0.6560.06
(Figure 2A) [29]. An average 6.360.7-fold induction of firefly
luciferase was obtained with treatment of cells with 2 mM sodium
butyrate (Figure 2B). The majority of compounds screened did not
induce firefly luciferase. As shown in the scattergram of fold-
induction of all 121,035 compounds screened (Figure 2C), only
564 compounds induced luciferase to greater than or equal to that
of the plate median+3SD, resulting in a hit rate of 0.49%. A
maximum fold-activation of .8-fold was obtained with some
compounds in the primary screen. The actives from the primary
screen were cherry-picked from mother plates and retested for
firefly luciferase induction in an eight concentration dose-response
(two fold dilution starting at 30 mM). Of 564 compounds, 328
compounds were dose-responsive with 83 compounds inducing
luciferase to greater than 2.5 fold. The compounds were subjected
to cheminformatics analysis to define the structural groups and the
range of activities within each group (data not shown). At least 12
distinct clusters were identified using the Tripos Selector program.
From each preliminary cluster, the largest conserved substructure
present in at least half of the cluster members was identified. These
data will used to guide efforts to progress these compounds
forward as potential therapeutics and assist in choosing additional
compound banks to screen.
Secondary assays
In order to establish that the firefly induction activity was not
due to breakdown products of library compounds, some of the
active compounds were repurchased as fresh powders (.95%
purity). Of the 121,035 compounds screened, 232 actives that met
the criteria outlined above, were identified and repurchased for
further testing and validation. The number of actives within the
232 hit set identified in the primary screen of the CID-dependent
dual luc BMCs that had c-firefly luciferase induction 2-fold or
higher was 211, thus 90% of the originally identified actives were
reconfirmed (Figure 3A). The activity of the repurchased com-
pounds was tested in a 10 concentration dose-response in the
following 3 cell-based assays using the same CID-dependent dual
luc BMCs used in the primary screen: 1) c-firefly luciferase
induction assay, 2) b-Renilla luciferase induction, and 3) cytotox-
icity assays (Figure 1B). In addition to the three cell-based assays, a
biochemical screen was set up using purified firefly luciferase to
identify compounds that directly inhibit luciferase enzyme activity.
Luciferase enzyme binders/modulators have been implicated in
stabilizing luciferase RNA and hence appear as false positives in
luciferase-based screens [30]. Based on these four secondary
assays, at least 124 compounds were found to specifically induce
firefly luciferase between 2- to 11-fold (Figure 3A), did not induce
b-globin promoter-Renilla luciferase, and were not cytotoxic to the
dual reporter-expressing BMCs (data not shown). None of the 124
compounds inhibited purified firefly luciferase.
Some of these compounds were tested in physiologically
relevant non-reporter assay systems [31]. Seven cherry-picked
repurchased compounds showed fold-induction of firefly luciferase
(Figure 3B). The corresponding induction of Renilla luciferase
activity is also shown in Figure 3B. These compounds were also
tested for their ability to inhibit firefly luciferase enzyme in a
biochemical assay (Figure 3C). The cytotoxicity of these com-
pounds in CID-dependent dual luc b-YAC BMCs is shown in
Figure 3D. All compounds were found to specifically up-regulate
firefly luciferase with no significant induction of the Renilla
reporter. While most of the compounds were not cytotoxic, a few
compounds were found to affect cell viability at higher concen-
trations. Compounds #1 and #157 appear to be less cytotoxic
than the control (Figure 3D); however in subsequent assays
described below these compounds did not have a stimulatory
effect on cell proliferation. Thus, the increased c-globin signal was
not a consequence of increased cell number.
Most of the firefly luciferase inducers did not significantly inhibit
the luciferase enzyme (IC50.100 mM). Table 3 shows the EC50
values for the molar concentrations of these compounds resulting
in 50% stimulation of firefly luciferase expression and their
corresponding IC50 values for the molar concentrations resulting
in 50% loss of cell viability. The therapeutic index for each
compound was calculated from the ratio of IC50 for cytotoxicity to
Figure 2. High-throughput screening for firefly luciferase inducers. Panel A) Distribution of Z9 scores. An average Z9 of 0.6560.067 was
obtained across all assay plates indicating suitability of the assay for high-throughput screening of 121,035 compounds. Panel B) Sodium butyrate-
induced firefly luciferase expression. The treatment of cells with the positive control sodium butyrate resulted in an average increase in firefly
luciferase expression by 6.360.77-fold across all 300 plates tested. Panel C) Scattergram of fold-induction of all 121,085 compounds tested using
CID-dependent dual-luc b-YAC BMCs. 564 active compounds were identified that induced firefly luciferase greater than 3 standard deviations above
the plate median.
doi:10.1371/journal.pone.0107006.g002
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Figure 3. Reconfirmation and secondary assays of c-globin inducer compounds. Panel A) Reconfirmation of c-luc inducibility by
232 actives from primary HTS. Four secondary assays were employed including two reconfirmation assays for firefly luciferase induction and
cytotoxicity, and two specificity assays for Renilla luciferase activity and luciferase enzyme modulators. All assays were a 10-point dose-response. A
summary of firefly induction is shown in this figure. 211 of the 232 compounds had firefly induction of 2-fold or higher; a 90% reconfirmation rate.
High-Throughput Screen for Fetal Hemoglobin Inducers
PLOS ONE | www.plosone.org 6 September 2014 | Volume 9 | Issue 9 | e107006
EC50 for luciferase stimulation. A larger window indicates
significant separation of stimulatory activity of the compound
from its cytotoxic effects. As shown in Table 3, the therapeutic
windows were found to be significant for a majority of the
compounds tested. Compound 1 with EC50 ,1.4 mM and no
detectable cytotoxicity exhibited the most favorable profile.
Fetal hemoglobin activation in CID-dependent wild-type
b-YAC BMCs
The HTS and initial validation of hits measured luciferase
activity from fusions to the c- and b-globin gene promoters. Thus,
an important first secondary assay was to demonstrate that our
actives effectively induced native c-globin mRNA and protein, as
well as the formation of HbF. For this purpose we utilized CID-
dependent BMCs derived from wild-type b-YAC transgenic mice
[26]. Criteria for cherry-picking compounds for testing in
secondary assays included those with the highest fold induction,
coupled with lowest toxicity. These are the top seven compounds
listed in the table from Figure 3A. Compound #1 was dropped
from further consideration because cell survival proved to be lower
than expected based on the HTS results.
To confirm the effectiveness of these compounds, human c- and
b-globin gene expression was measured by qPCR in RNA samples
from wild-type b-YAC BMCs treated with the 6 remaining
compounds (Figure 4). c-globin expression increased 26.9-fold
with compound #42 and 13.6-fold with compound #208.
Compounds #7 and #87 also induced c-globin expression (3.7-
and 2.3-fold, respectively). Sodium butyrate (NaB) and DMSO
treatment was performed in parallel as a positive control and
solvent control, respectively; 9.9-fold induction of c-globin
expression was observed with NaB treatment. Two of the
compounds did not increase c-globin transcription (#125 and
#157). No induction of adult b-globin was observed with any of
the 7 compounds tested.
c-globin (HbF)-expressing F cells were measured in parallel to
confirm the induction of c-globin expression at the protein level.
Compound #208 showed 16% F cells and compound #42 had
14.1% F cells, compared to 15.9% F cells with NaB treatment and
no change in F cells in DMSO only-treated and untreated samples
(Figure 5A). These results are consistent with the induction of c-
globin observed at mRNA levels. Interestingly, compounds #7
and #87 showed higher induction of c-globin at the protein level
than mRNA, with 12.3% and 9.9% F cells (Figure 5A). The
change in number of cells expressing c-globin ranged from 14-46-
fold (compounds #125 and #157 not included) compared to
untreated cells, and in general, mirrored the % F cells measured
(Figure 5B). Compound #42 was an exception with fewer cells
expressing c-globin compared to the number of F cells, whereas
the opposite was true for compound # 87 and especially for
compound #208. For compound # 208 this outcome might have
been related to lower viability of cells following treatment
(Figure 5C).
Based on the RT-qPCR and flow cytometry data for the six
compounds assessed, #125 and #157 were dropped from further
analyses based on lack of c-globin transcript induction. Change in
HbF was measured by ELISA following treatment with the
remaining compounds in the wild-type b-YAC BMCs, as
described in Materials and Methods. The pattern of expression
of HbF by ELISA was similar to the mRNA expression results
(Figure 5D). Treatment with compound #42 produced the
greatest increase in HbF with the least variability, followed by
compound #208 (with much greater variability), and then
compound #7. The smallest response was seen with compound
#87. The variation in response to #208 may be related to the
much larger decrease in viability we observed with this compound
(40%; Figure 5C)
Fetal hemoglobin activation in human primary erythroid
progenitor cells
Our last set of studies was aimed at demonstrating the ability of
the lead compounds to induce HbF expression in human erythroid
progenitors generated in liquid cultures. CD34+ cells were
cultured in a 2-stage system as described in Materials and
Methods. Initial studies were performed to monitor terminal
erythroid maturation and the c- to b-globin switch in this system.
Cells were harvested every 2–3 days and morphology was
examined by Giemsa staining. We observed a steady progression
of erythropoiesis with 19% reticulocytes and mature red blood
cells by day 14 (Figure 6A). We next performed qRT-PCR to
follow the c- to b-globin switch, which was observed around day
10 in culture (Figure 6B). These data support the use of this system
to test the ability of lead compounds to activate human c-globin.
Panels B-D) Performance of seven c-firefly inducers in the initial four secondary assays – detailed 10-point dose-response data.
Comparison of compound activity from dose-response data is shown for firefly and Renilla luciferase activity (Panel B), purified firefly luciferase
enzyme inhibition (Panel C), and cytotoxicity (Panel D). Assays were performed as described in Materials and Methods.
doi:10.1371/journal.pone.0107006.g003
Table 3. EC50, IC50 and therapeutic index for seven cherry-picked compounds.
Firefly Luciferase Cytotoxicity
Compound ID EC50 (mM) Fold-induction IC50 (mM) Therapeutic Index
1 1.4 8.6 .100 .100
7 5.9 6.5 87.6 15
42 9.8 5.2 .100 .100
87 49.3 9.6 .100 .100
125 5.7 7.0 35.0 6
157 30.0 9.5 .100 .100
208 14.3 10.1 24.3 2
.100: Less than 10% or no cytotoxicity up to 100 mM tested.
doi:10.1371/journal.pone.0107006.t003
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The various compounds were added on day 8 for 48 hours and
cell viability, measured by trypan blue exclusion, remained greater
than 97% throughout the culture period. Using qRT-PCR, the c-
globin to b-globin (c/b) ratio was increased 1.8-fold for the
positive control sodium butyrate when compared to DMSO
(Figure 6C). In contrast, the c/b ratio for lead compounds #7,
#42, #87 and #208 was increased 2.8-, 2.9-, 1.6- and 2.2-fold,
respectively.
FACS analysis was conducted to determine if the lead
compounds induce HbF synthesis in erythroid progenitors by
measuring the % HbF-positive cells (Figure 7A). We observed a 7-
fold increase in % HbF-positive cells after sodium butyrate
treatment compared to a 2.7-5.1-fold increase mediated by the
lead compounds (Figure 7B). DMSO alone did not change the
levels of HbF-positive cells significantly. These data demonstrate
the ability of the lead compounds #7, #42, #87 and #208 to act
as HbF-inducers in human primary erythroid cells.
Discussion
Proteins with potential therapeutic value must meet the criteria
implied or predicted for druggable targets based on evolutionary
relationships, 3D-structural properties, features derived from
amino-acid sequence or properties of ligands known to bind the
protein. Proteins with narrow specificity for regulating c-globin
gene expression constitute potential ideal druggable targets, but
none have been identified. Alternate approaches utilized molec-
ular modeling to identify new therapeutic candidates based on
compounds previously shown to induce HbF, such as short-chain
fatty acids and derivatives [32], a chemical genetic strategy in
primary cells for HDAC1 and 2 inhibitors [33], an optical assay in
which the color is proportional to the anti-sickling effect of the test
compound [34] or a more naı̈ve cell-based c-globin expression
reporter HTS assay [35]. This latter approach relied on phenotype
(c-globin induction, enhanced HbF expression) to identify useful
agents, rather than searching for compounds or ligands that
directly affect a target protein. The lack of fetal c-globin-specific
regulatory proteins that meet druggability criteria has made this
approach the method of choice for identification of potential new
therapeutic compounds to treat b-hemoglobinopathies. Research
on c-globin gene regulation may result in the discovery of fetal-
specific activators or repressors that may be druggable. In the
meantime, phenotypic selection for HbF chemical inducers using
assays amenable to HTS of large compound libraries will allow
exhaustive assessment of all available compound and drug
libraries.
The reporter assay in the cell-based HTS mentioned above was
not robust [34], but the cell-based system we developed provides a
tightly-regulated c-globin expression ‘‘off-on’’ switch with a
readout that was adapted for HTS. Identification of pharmaco-
logic agents capable of reactivating c-globin gene expression has
been complicated by the lack of suitable cell lines. Essentially, cell
lines were not available that displayed a suitable ‘‘off-on’’ switch
for c-globin gene expression, including mouse human globin
transgenic MEL cells, HFE-MEL switching hybrids, and human
K562 or HEL cells. We rationalized that a better approach would
be to use primary progenitors derived from b-YAC transgenic
mouse bone marrow using a novel method to immortalize these
cells [24], [26], [36]. A CID was used to specifically and reversibly
control the growth of primary, multi-potential hematopoietic cell
populations in vitro and establish cell culture. In CID-dependent
wild-type b-YAC BMCs, b-globin is expressed, but c-globin
expression is not detectable. However, expression is inducible
using a variety of drugs known to increase HbF. Endogenous
mouse bmaj-globin and a-globin are also synthesized [26].
Figure 4. c-globin and b-globin mRNA levels in compound-treated CID-dependent wild-type b-YAC mouse bone marrow cells. qRT-
PCR was performed as described in Materials and Methods. Fold change in mRNA level is shown on the y-axis; sample names are shown on the x-axis.
Ctrl, untreated cells; DMSO, cells treated with DMSO only; NaB, 2 mM sodium butyrate; #7, 50 mM; #42, 15 mM, #87; 100 mM; #125, 30 mM; #157,
100 mM; #208-25, 25 mM. Gray bars, c-globin mRNA expression; black bars, b-globin mRNA expression. Data shown are the results of two-three
separate experiments, with each sample duplicated within an experiment. P#0.01 for NaB and compound # 42; P#0.05 for compounds #42 and
#208.
doi:10.1371/journal.pone.0107006.g004
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Addition of erythropoietin (Epo) and stem cell factor (SCF)
modestly enhance globin gene expression; a cocktail of Epo,
granulocyte monoctye-colony stimulating factor (GM-CSF) and
interleukin-3 (IL-3) does not. BMCs derived from -117 Greek
HPFH b-YAC transgenic mice [37] recapitulated the HPFH
phenotype. A c-globin-specific synthetic Zn finger activator
protein (gg1-VP64) [38], [39] induced c-globin synthesis in wild-
type b-YAC BMCs, as does enforced expression of other fetal-
specific transcriptional activators including FKLF and FGIF [26].
Differentiation into terminal erythrocytes is not required, since
globin gene expression patterns are similar in both our BMC and
erythroid cell populations.
CID-dependent bone marrow cells were established from Ac-luc
b-luc b-YAC transgenic mice. These cells were utilized to develop
and benchmark a robust HTS assay to identify compounds that 1)
induced c-globin gene expression, 2) did not induce b-globin gene
Figure 5. Induction of HbF by lead compounds in CID-dependent mouse BMCs. Panel A) FACS analysis of HbF levels in compound-
treated CID-dependent wild-type b-YAC mouse bone marrow cells. The protocol was carried out as described in Materials and Methods
using anti-human HbF FITC-conjugated antibody. Samples are labeled as described in the legend to Figure 4, but compound concentration follows
the compound number. Representative data from one experiment is shown here, but the experiment was replicated two to three times for each
sample with similar results (summarized in Panels B and C). Panels B-C) Summary of FACS analysis of HbF levels in compound-treated CID-
dependent wild-type b-YAC mouse bone marrow cells. Panel B) fold change in c-globin (FITC)+ cells. Panel C) percent viable cells. Bars show
mean and standard error of the mean in control and compound-treated cells for each panel. Panel D) HbF induction measured by ELISA in
compound-treated CID-dependent wild-type b-YAC mouse bone marrow cells. The assay was carried out as described in Materials and
Methods. Fold induction of HbF is shown on the y-axis; cell treatment and concentration, where applicable, are shown on the x-axis. Data represent
the mean and standard error of the mean from four experiments with duplicate samples within each experiment.
doi:10.1371/journal.pone.0107006.g005
Figure 6. c-globin expression is induced in compound-treated human primary erythroid progenitors. Human erythroid progenitors
were generated from adult CD34+ cells in liquid culture as described in Materials and Method). Cells were analyzed for morphology, globin gene
expression and HbF induction after treatment with the lead compounds. Panel A) Erythroid cells were harvested on the days indicated for cell
morphology determination by Geimsa staining. The percentage of different erythroid progenitors at each stage is shown as a function of days in
culture. At least 500 cells were counted by light microscopy from duplicate slides. Representative cell morphology is shown in the images at 406
magnification. Panel B) qRT-PCR was performed as described in Materials and Methods. The levels of c- and b-globin expression were normalized to
GAPH; expression of each gene is shown as a fraction of the total globin (c+b). Note the c-to b-globin switch around day 10. Panel C) Fold change in
c-globin/b-globin mRNA ratio after normalization to GAPDH is shown on the y-axis. UN, untreated cells; DMSO, cells treated with DMSO only; NaB,
2 mM sodium butyrate; lead compounds: #7, 50 mM; #42, 15 mM, #87; 100 mM; #208, 25 mM. Data shown are the mean and standard error of the
mean of three independent samples.
doi:10.1371/journal.pone.0107006.g006
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expression, 3) were not cytotoxic and 4) did not directly affect
luciferase enzymatic activity. The HTS surveyed 121,035 com-
pounds from various libraries and yielded 232 hits that induced c-
luc 2- to 11-fold. Of these, 211 were reconfirmed for c-luc
induction, and 124 met the constraints of the four listed criteria
following a 4-assay, 10 point dose-response secondary screen. Six
of the top 124 actives were cherry-picked for further analysis and
conformation in other cell-based systems.
Our first assessment was in wild-type b-YAC BMCs, where
normal c-globin transcript and protein levels could be measured in
the multi-potential mouse BMC background, rather than lucifer-
ase activity. Using the optimum dose for each compound, four of
the six compounds induced c-globin transcription 2- to 26-fold
and had increased F cells ranging from 9.9 to 16% in wild-type b-
YAC BMCs. ELISA concurred with these data; an approximately
2- to 4-fold increase in HbF was observed; the same pattern of
change seen in mRNA levels was reflected in protein levels.
Although different cell lines have been used extensively to
screen chemical compound libraries for HbF inducers, these lines
do not undergo hemoglobin switching. Thus, the output of these
screens may yield false-positive hits that do not correlate with their
ability to induce HbF in primary human erythroid progenitors.
The dual luciferase reporter system established in primary mouse
BMCs immortalized by the CID and used for the HTS described
in this report more closely mimics human erythroid progenitors.
Our studies in erythroid progenitors generated from adult human
primary CD34+ stem cells confirmed the validity of using the CID-
dependent b-YAC BMCs for the HTS. In addition, the data
demonstrated that this system recapitulated erythropoiesis and the
c to b-globin switch in a manner similar to that previously
published using another liquid culture system [40], [41]. The
advantage of the human progenitor terminal differentiation
protocol is that we produce mature erythrocytes and mimic the
c- to b-globin switch similar to normal erythropoiesis in vivo,
thereby adding further credibility to our hit identification. The fact
that HbF was induced by lead compounds #7, #42, #87 and
#208 to levels greater than sodium butyrate suggests that these
agents are candidates for further drug development using
medicinal chemistry approaches to treat b-hemoglobinopathies.
Figure 7. The lead compounds induce HbF expression in human primary erythroid cells. FACS analysis was performed with erythroid
progenitors treated for 48 hours with each of the four lead chemical compounds. The protocol was carried out as described in Materials and Methods
using anti-human HbF FITC-conjugated antibody. Panel A) Representative FACS tracings are shown; experiments were replicated three times for
each compound with similar results. Panel B) Based on the FACS data the % HbF-positive cells (FITC-A) was calculated for the different treatment
conditions. Shown in the graph is the fold change in HbF-positive cells. Data are shown as the mean and standard error of the mean in control and
compound-treated cells for each sample. *; P,0.01.
doi:10.1371/journal.pone.0107006.g007
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